Reference is made to the stock exchange announcement of 14 May 2019 regarding the proposed restructuring of Navamedic ASA (the "Company" or "NAVA" and together with its direct and indirect subsidiaries, the "NAVA group"), whereby the Company's Medtech division is demerged from the Company and merged into a newly incorporated entity, Observe Medical ASA ("OM ASA" and together with its direct and indirect subsidiaries following the completion of the demerger, the "OM ASA group"), which will be listed on Oslo Axess upon completion of the demerger.
Please see the attached PDF for the release including financial effects of the demerger.
For further information, please contact:
Toril Ås, CFO, Navamedic
Mobile: +47 957 01 071
Kathrine Gamborg Andreassen, CEO,
Navamedic Mobile: +47 951 78 680